Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Medina Lee, Luis David"'
Autor:
Martínez García, Luisa Fernanda, Martin Arsanios, Daniel Augusto, Estupiñán Monsalv, Alvaro Miguel, Restrepo Martínez, Juan Manuel, Perdomo Rodríguez, Laura Sofía, Delgado Cañaveral, Maria Camila, Medina Lee, Luis David
Publikováno v:
In Kidney International Reports April 2024 9(4) Supplement:S6-S8
Publikováno v:
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J [Internet]. 2015;46(4):903–75.
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(Suppl):D42–D50.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;24;53(1):1.
Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med. 2017;141(5):696.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.
López Reyes R, Nauffal Manzur D, Garcia Ortega A, Menéndez Salinas MA, Ansotegui Barrera E, Balerdi Perez B. Clinical characteristics and survival of patients with pulmonary hypertension: a 40-month mean follow-up. Clin Respir J. 2017];11(1):103–12.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012; 142(2):448–56.
Scherrer U, Allemann Y, Rexhaj E, Rimoldi SF, Sartori C. Mechanisms and drug therapy of pulmonary hypertension at high altitude. High Alt Med Biol. 2013;14(2):126–33.
Gali N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31(17):2080–6.
Kemp K, Savale L, O’Callaghan DS, Jaís X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. J Hear Lung Transplant. 2012;31(2):150–8.
Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin V V., et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med [Internet]. 2015; 373(9):834–44.
Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314–22.
Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: The future is here. Eur Respir Rev. 2012;21(126):321–7.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–36.
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(Suppl):D51–D59.
Gerges C, Gerges M, Skoro-Sajer N, Zhou Y, Zhang L, Sadushi-Kolici R, Jakowitsch J, Lang MB, Lang IM, Hemodynamic thresholds for pre-capillary pulmonary hypertension, CHEST (2015), doi: 10.1378/chest.15-0928.
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2018; in press [https://doi.org/10.1183/13993003.01904-2018.
Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic characterization of EIF2AK4 mutation carrier in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 2017; 136: 2022–2033.
Rostagno C, Galanti G, Comeglio M, Boddi V, Olivo G, Gastone Neri Serneri G. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail. 2000 Sep;2(3):273-80.
Baba, M., Yoshida, K., & Ieda, M. Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. International Journal of Molecular Sciences. 2019; 20 (11), 2824. doi:10.3390/ijms20112824.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.
Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.
Curr Cardiovasc Risk Rep. 2021;15(1):2. doi: 10.1007/s12170-020-00663-3. Epub 2020 Nov 18.
Simonneau, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American journal of respiratory and critical care medicine. 2002; 165(6), 800–804.
Eur Respir J. 2014 Jun;43(6):1691-7. doi: 10.1183/09031936.00116313. Epub 2014 Mar 13.
Badagliacca, R., Pezzuto, B., Poscia, R., Mancone, M., Papa, S., Marcon, S., … Vizza, C. D. (2012). Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. The Journal of Heart and Lung Transplantation, 31(4), 364–372. doi:10.1016/j.healun.2011.12.011
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(Suppl):D42–D50.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;24;53(1):1.
Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med. 2017;141(5):696.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.
López Reyes R, Nauffal Manzur D, Garcia Ortega A, Menéndez Salinas MA, Ansotegui Barrera E, Balerdi Perez B. Clinical characteristics and survival of patients with pulmonary hypertension: a 40-month mean follow-up. Clin Respir J. 2017];11(1):103–12.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012; 142(2):448–56.
Scherrer U, Allemann Y, Rexhaj E, Rimoldi SF, Sartori C. Mechanisms and drug therapy of pulmonary hypertension at high altitude. High Alt Med Biol. 2013;14(2):126–33.
Gali N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31(17):2080–6.
Kemp K, Savale L, O’Callaghan DS, Jaís X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. J Hear Lung Transplant. 2012;31(2):150–8.
Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin V V., et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med [Internet]. 2015; 373(9):834–44.
Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314–22.
Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: The future is here. Eur Respir Rev. 2012;21(126):321–7.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–36.
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(Suppl):D51–D59.
Gerges C, Gerges M, Skoro-Sajer N, Zhou Y, Zhang L, Sadushi-Kolici R, Jakowitsch J, Lang MB, Lang IM, Hemodynamic thresholds for pre-capillary pulmonary hypertension, CHEST (2015), doi: 10.1378/chest.15-0928.
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2018; in press [https://doi.org/10.1183/13993003.01904-2018.
Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic characterization of EIF2AK4 mutation carrier in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 2017; 136: 2022–2033.
Rostagno C, Galanti G, Comeglio M, Boddi V, Olivo G, Gastone Neri Serneri G. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail. 2000 Sep;2(3):273-80.
Baba, M., Yoshida, K., & Ieda, M. Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. International Journal of Molecular Sciences. 2019; 20 (11), 2824. doi:10.3390/ijms20112824.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.
Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.
Curr Cardiovasc Risk Rep. 2021;15(1):2. doi: 10.1007/s12170-020-00663-3. Epub 2020 Nov 18.
Simonneau, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American journal of respiratory and critical care medicine. 2002; 165(6), 800–804.
Eur Respir J. 2014 Jun;43(6):1691-7. doi: 10.1183/09031936.00116313. Epub 2014 Mar 13.
Badagliacca, R., Pezzuto, B., Poscia, R., Mancone, M., Papa, S., Marcon, S., … Vizza, C. D. (2012). Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. The Journal of Heart and Lung Transplantation, 31(4), 364–372. doi:10.1016/j.healun.2011.12.011
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: El tratamiento de la hipertensión pulmonar arterial es un reto clínico, ya que requiere una estrategia compleja y multidisciplinaria, fundamentada en el uso de vasodilatadores pulmonares. Las investigaciones actuales se enfocan princ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85cbf8a483b7b09d730b237df5a21cbf
https://repository.urosario.edu.co/handle/10336/32223
https://repository.urosario.edu.co/handle/10336/32223
Autor:
Hernández-Sómerson, Mario Andrés, Huertas-Rodríguez, Gustavo, Medina-Lee, Luis David, Ortiz-Arroyo, Jaime, Pabón-Barrera, Johanna, Escobar-Sáenz, Jaime Andrés
Publikováno v:
Medicina Interna de Mexico; mar/abr2022, Vol. 38 Issue 2, p366-377, 12p